- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02603276
Lipid-lowering Effect of Phytosterols, Red Yeast Rice and Their Combination
January 30, 2024 updated by: Claudio Borghi, University of Bologna
Lipid-lowering Effect of Phytosterols, Red Yeast Rice and Their Combination in Moderately Hypercholesterolemic Subjects in Primary Prevention for Cardiovascular Diseases: a Randomized, Double Blind, Clinical Trial
A large body of evidence confirm the cholesterol lowering effect of phytosterols and red yeast rice.
Because their mechanisms of action mime the ones of chemical statins and cholesterol absorption inhibitors, it is plausible that their association will provide a more relevant (and safe) LDL cholesterolemia reduction.
Study Overview
Status
Completed
Conditions
Detailed Description
A large body of literature suggest that the patients are strongly interested in self-medicating them with "natural" products aimed at reducing their plasma level of LDL-cholesterol.
Plant sterols and red yeast rice are among the most widely marketed product with these properties in Western countries.
However plant sterols per se have a limited effect on cholesterolemia, while full dosed red yeast rice can induce myalgias and myopathies as statins do.
In this context, the aim of the investigators' study was to evaluate if the association of both products at low dosage could induce an additive or synergistic effect in term of LDL-reduction in humans.
Study Type
Interventional
Enrollment (Estimated)
60
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Bologna, Italy, 40038
- S. Orsola-Malpighi University Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years to 68 years (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- LDL-cholesterolemia between 130 and 190 mg/dL
Exclusion Criteria:
- Type 2 diabetes
- Previous cardiovascular disease
- Assumption of lipid-lowering drugs or dietary supplements
- Previous intolerance to red yeast rice
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Plant sterols
Plant sterols 800 mg per dose, 1 liquid stick per day, per 8 weeks
|
Plant sterols 800 mg/dose, 1 liquid stick per day, for 8 weeks
|
Active Comparator: Red Yeast Rice
Red Yeast Rice 200 mg containing 5 mg monacolin K per daily dose, 1 liquid stick per day, per 8 weeks
|
Red Yeast Rice titrated in 5 mg monacolin K per daily dose, 1 liquid stick per day, for 8 weeks
|
Experimental: Red Yeast Rice plus Plant sterols
lant sterols 800 mg per dose + Red Yeast Rice 200 mg containing 5 mg monacolin K per daily dose, 1 liquid stick per day, per 8 weeks
|
Plant sterols 800 mg/dose, 1 liquid stick per day, for 8 weeks
Red Yeast Rice titrated in 5 mg monacolin K per daily dose plus Plant sterols 800 mg/dose, together in 1 liquid stick per day, for 8 weeks
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
LDL cholesterolemia reduction from baseline and between groups
Time Frame: 8 weeks
|
Absolute and % reduction of LDL cholesterolemia after 8 weeks of treatment
|
8 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Non-HDL cholesterolemia reduction from baseline and between groups
Time Frame: 8 weeks
|
Absolute and % reduction of of non-HDL cholesterolemia after 8 weeks of treatment
|
8 weeks
|
Number of Participants With Treatment-Related Adverse Events
Time Frame: 8 weeks
|
Subjective tolerability of the tested treatment
|
8 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Claudio Borghi, MD, University of Bologna
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
April 1, 2015
Primary Completion (Actual)
December 1, 2015
Study Completion (Actual)
December 1, 2015
Study Registration Dates
First Submitted
August 27, 2015
First Submitted That Met QC Criteria
November 9, 2015
First Posted (Estimated)
November 11, 2015
Study Record Updates
Last Update Posted (Actual)
February 1, 2024
Last Update Submitted That Met QC Criteria
January 30, 2024
Last Verified
January 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Metabolic Diseases
- Lipid Metabolism Disorders
- Hyperlipidemias
- Dyslipidemias
- Hypercholesterolemia
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antimetabolites
- Anticholesteremic Agents
- Hypolipidemic Agents
- Lipid Regulating Agents
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
- Red yeast rice
Other Study ID Numbers
- PhytoRed
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypercholesterolemia
-
National Medical Research Center for Therapy and...Moscow State University of Medicine and DentistryRecruitingMedication Adherence | Adherence, Medication | Treatment Adherence | Familial Hypercholesterolemia | Motivational Interviewing | Adherence, Patient | Treatment Adherence and Compliance | Patient Compliance | Adherence | Hypercholesterolemia, Familial | Patient Adherence | Hypercholesterolemia, Autosomal Dominant and other conditionsRussian Federation
-
Direct PlantesUnknownHYPERCHOLESTEROLEMIAFrance
-
Chong Kun Dang PharmaceuticalRecruitingPrimary HypercholesterolemiaKorea, Republic of
-
Addpharma Inc.CompletedPrimary HypercholesterolemiaKorea, Republic of
-
JW PharmaceuticalCompletedPrimary HypercholesterolemiaKorea, Republic of
-
Hanmi Pharmaceutical Company LimitedCompletedPrimary HypercholesterolemiaKorea, Republic of
-
Provident Clinical ResearchGlaxoSmithKlineUnknownPrimary HypercholesterolemiaUnited States
-
Organon and CoCompletedPrimary Hypercholesterolemia | Homozygous Familial Hypercholesterolemia
-
Boryung Pharmaceutical Co., LtdRecruitingPrimary HypercholesterolemiaKorea, Republic of
-
Ahn-Gook Pharmaceuticals Co.,LtdRecruitingPrimary HypercholesterolemiaKorea, Republic of
Clinical Trials on Plant sterols
-
Unilever R&DCompletedHealthy | Mildly Elevated Cholesterol LevelsSweden
-
Danone JapanCompletedNormal and Mild Hypercholesterolemic SubjectsJapan
-
University of HelsinkiUniversity of Eastern FinlandUnknown
-
Danone ResearchCompletedMild Hypercholesterolemic SubjectsGermany
-
Jose Rocha Faria NetoCompleted
-
Danone ResearchCompletedHypercholesterolemiaUnited States
-
Danone ResearchCompletedMildly Hypercholesterolemic SubjectsItaly
-
Unilever R&DCommonwealth Scientific and Industrial Research Organisation, AustraliaCompletedVascular Diseases | Diabetes Mellitus | HypercholesterolemiaAustralia
-
University Hospital, SaarlandUnknown
-
Danone JapanCompletedHealthy | Mild HypercholesterolemiaJapan